Immunovant Historical Valuation

IMVT -  USA Stock  

USD 8.30  0.17  2.01%

Some fundamental drivers such as market cap or Immunovant enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Immunovant valuation indicators such as Enterprise Value of 1.2 B or Market Capitalization of 1.5 B to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Immunovant's future value. Financial Statement Analysis is much more than just reviewing and breaking down Immunovant prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunovant is a good buy for the upcoming year.
Please see Risk vs Return Analysis.

Immunovant Historical Statements 

 
Refresh
Share

About Immunovant Valuation Data Analysis

Valuation is the financial process of determining what Immunovant is worth. Immunovant valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Immunovant valuation ratios help investors to determine whether Immunovant Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovant with respect to the benefits of owning Immunovant security.

Immunovant Valuation Data Chart

Immunovant valuation ratios help to determine how cheap or expensive it is, compared to its peers or based on some benchmark measure of value for a given date. A typical valuation ratio shows the difference between the cost of Immunovant equity instrument and the benefits of owning shares of Immunovant.

Average Assets

Average asset value for the period used in calculation of Return on Average Equity and Return on Average Assets; derived from Total Assets.

Enterprise Value

Enterprise Value (or EV) is usually referred to as Immunovant theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Immunovant debt, but would also pocket its cash. Enterprise Value is more accurate representation of Immunovant value than its market capitalization because it takes into account all of Immunovant existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.

Market Capitalization

Market capitalization (or market cap) is the total value of the shares outstanding of Immunovant. It is equal to Immunovant current share price times the number of Immunovant outstanding shares. Represents the product of [SharesBas]; [Price] and [ShareFactor].
Most indicators from Immunovant valuation accounts are interrelated and interconnected. However, analyzing valuation accounts indicators one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of valuation accounts indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.
 2010 2020 2021 (projected)
Enterprise Value755.2 M1.15 B1.16 B
Average Equity53.98 M377.95 M323.96 M

Immunovant valuation accounts Correlations

Immunovant Account Relationship Matchups

Immunovant Investors Sentiment

The influence of Immunovant's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunovant. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - IMVT

Immunovant Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunovant. What is your judgment towards investing in Immunovant? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunovant using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.